T. Rowe Price Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

T. Rowe Price Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,638	Closed	-$28K	–	928
2025 Q3	$28K	Sell	12,638 -169,798	-93%	-$401K	﹤0.01%	670
2025 Q2	$314K	Sell	182,436 -1,747,584	-91%	-$4.35M	﹤0.01%	655
2025 Q1	$6.43M	Sell	1,930,020 -3,904,436	-67%	-$20.1M	﹤0.01%	579
2024 Q4	$43.2M	Sell	5,834,456 -26,823	-0.5%	-$249K	0.03%	428
2024 Q3	$55M	Buy	5,861,279 +3,810,779	+186%	+$36.1M	0.03%	393
2024 Q2	$16.4M	Buy	2,050,500 +737,161	+56%	+$7.9M	0.01%	519
2024 Q1	$19.5M	Buy	+1,313,339	New	+$15.3M	0.01%	504

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management's IOVA Position: Q4 2025 in Review

T. Rowe Price Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2025, closing a stake of 12,638 shares — an estimated $28K sold.

T. Rowe Price Investment Management first reported a position in IOVA in Q1 2024 and held it in 7 quarters. The position peaked at $55M in Q3 2024. 264 funds tracked by Wall St. Rank hold IOVA as of Q4 2025.

T. Rowe Price Investment Management reported no remaining Iovance Biotherapeutics position as of Q4 2025 after selling out during the quarter.
T. Rowe Price Investment Management sold 12,638 Iovance Biotherapeutics shares in Q4 2025, an estimated $28K.
T. Rowe Price Investment Management first reported a position in Iovance Biotherapeutics in Q1 2024 and held it in 7 quarters.
T. Rowe Price Investment Management's Iovance Biotherapeutics position peaked at $55M in Q3 2024.
264 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.